ALDH5A1

(redirected from SSADH)

ALDH5A1

A gene on chromosome 6p22 that encodes mitochondrial matrix NAD-dependent succinic semialdehyde dehydrogenase, of the aldehyde dehydrogenase family of proteins.

Molecular pathology
ALDH5A1 mutation causes 4-hydroxybutyricaciduria, which, due to an inability to metabolise GABA, results in accumulation of GHB, a neuromodulator.
References in periodicals archive ?
In the gastrodin-treated group, both succinic semialdehyde dehydrogenase (SSADH) and succinic semialdehyde reductase (SSAR) immunoreactivities in the hippocampus was also decreased significantly, which stood in contrast to the nontreated group, in which strong SSADH and SSAR immunoreactivities were detected.
2 [micro]M, and scutellarein exhibited the best inhibitory effect on SSADH with an [IC.
In fact, the administration of GABA-T and SSADH inhibitors such as vigabatrin (Valdizan et al.
breviscapus extract and its flavonoid components including scutellarin on GABA and SSADH, and have described the structure-activity relationships of these compounds, in order to develop new therapeutic applications of E.
SSADH were isolated from adult, male, Sprague--Dawley rats according to the procedure of Nguyen and Picklo (2003) with slight modifications.
GABA-T activity was determined by measuring the formation of NADH upon the conversion of SSADH using a Hitachi FL-4500 Fluorescence Spectrophotometer (excitation 355 nm, emission 459 nm).
SSADH activity was assayed using the modified procedure of Chambliss and Gibson (1992).
breviscapus extract on both GABA-T and SSADH was investigated.
Mike Gibson, PhD, is a world-renowned expert and researcher on SSADH.
Sam did not respond to medication commonly used in SSADH but did respond to physical, occupational, and speech therapies.